Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2021 2
2022 9
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.
Gnant M, Fitzal F, Rinnerthaler G, Steger GG, Greil-Ressler S, Balic M, Heck D, Jakesz R, Thaler J, Egle D, Manfreda D, Bjelic-Radisic V, Wieder U, Singer CF, Melbinger-Zeinitzer E, Haslbauer F, Sevelda P, Trapl H, Wette V, Wimmer K, Gampenrieder SP, Bartsch R, Kacerovsky-Strobl S, Suppan C, Brunner C, Deutschmann C, Soelkner L, Fesl C, Greil R; Austrian Breast and Colorectal Cancer Study Group. Gnant M, et al. Among authors: brunner c. N Engl J Med. 2021 Jul 29;385(5):395-405. doi: 10.1056/NEJMoa2104162. N Engl J Med. 2021. PMID: 34320285 Clinical Trial.
Expert Discussion: ASCO 2022.
Balic M, Wimmer K, Suppan C, Silovski T, Brunner C. Balic M, et al. Among authors: brunner c. Breast Care (Basel). 2022 Aug;17(4):430-436. doi: 10.1159/000525966. Epub 2022 Jul 8. Breast Care (Basel). 2022. PMID: 36156916 Free PMC article. No abstract available.
Long-Term Outcomes of Adjuvant Denosumab in Breast Cancer.
Gnant M, Frantal S, Pfeiler G, Steger GG, Egle D, Greil R, Fitzal F, Wette V, Balic M, Haslbauer F, Melbinger-Zeinitzer E, Bjelic-Radisic V, Artner-Matuschek S, Kainberger F, Ritter M, Rinnerthaler G, Sevelda P, Bergh J, Kacerovsky-Strobl S, Suppan C, Brunner C, Deutschmann C, Gampenrieder SP, Fohler H, Jakesz R, Fesl C, Singer C. Gnant M, et al. Among authors: brunner c. NEJM Evid. 2022 Dec;1(12):EVIDoa2200162. doi: 10.1056/EVIDoa2200162. Epub 2022 Nov 18. NEJM Evid. 2022. PMID: 38319865 Clinical Trial.
Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update.
Rinnerthaler G, Singer C, Petru E, Egle D, Petzer A, Pluschnig U, Gampenrieder SP, Pfeiler G, Gnant M, Grünberger B, Krippl P, Strasser-Weippl K, Suppan C, Brunner C, Pusch R, Sandholzer M, Balic M, Bartsch R. Rinnerthaler G, et al. Among authors: brunner c. Wien Klin Wochenschr. 2022 Oct;134(19-20):683-692. doi: 10.1007/s00508-022-02082-3. Epub 2022 Sep 23. Wien Klin Wochenschr. 2022. PMID: 36149495 Free PMC article.
A retrospective validation of CanAssist Breast in European early-stage breast cancer patient cohort.
Gunda A, Basavaraj C, Serkad V CP, Adinarayan M, Kolli R, Siraganahalli Eshwaraiah M, Saura C, Ruiz F, Gomez P, Peg V, Jimenez J, Sprung S, Fiegl H, Brunner C, Egle D, Bhattacharyya GS, Bakre MM. Gunda A, et al. Among authors: brunner c. Breast. 2022 Jun;63:1-8. doi: 10.1016/j.breast.2022.02.010. Epub 2022 Feb 22. Breast. 2022. PMID: 35245746 Free PMC article.
16 results